Latest / Stock Movers / Novo Nordisk Slips, Fresenius & Telefónica Earnings
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News, The.
- 0:08Speaker 2: Stock Movers Report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Let's look at some of the stocks we'll move today
- 0:18Speaker 3: here in Europe. I'm Caroline Heckut with Stephen Carroll and
- 0:21Speaker 3: we joined by Bloomberg reporter at Chloe Malay.
- 0:23Speaker 1: Good morning, Chloe.
- 0:25Speaker 3: So let's start with Nova Nordisk and what's been happening
- 0:28Speaker 3: is inquite a lot moving in recent days for this business.
- 0:32Speaker 1: Yeah.
- 0:32Speaker 4: Absolutely, It's not been a really great start to the
- 0:36Speaker 4: year for Novas and the latest kind of big setback
- 0:39Speaker 4: that they had to deal with was the disappointing data
- 0:42Speaker 4: that we got yesterday on it's our next generation obesity shot,
- 0:46Speaker 4: and that is an ABC shot that is not working
- 0:48Speaker 4: as well as the rival product that we've got from
- 0:51Speaker 4: Elay Lilly.
- 0:52Speaker 1: And so the.
- 0:53Speaker 4: Readoubt was called the worst case scenario by Morgan Stanley
- 0:56Speaker 4: analysts yesterday and the shes fell massively as a result,
- 1:00Speaker 4: and today we're seeing some of that weakness continue because
- 1:04Speaker 4: we have now some analysts downgrading that stock on the
- 1:07Speaker 4: back of that disappointing data. So an ovn Ordisk was
- 1:11Speaker 4: cut to neutral rating at JP Morgan. It was also
- 1:14Speaker 4: cut at Naudea, and then the price target was also
- 1:17Speaker 4: cut at Intron Health, so kind of.
- 1:19Speaker 1: Cut across the board. And the problem.
- 1:21Speaker 4: Now for and Novo is that it really does need
- 1:24Speaker 4: a catalyst because the shares tumbled as well earlier this
- 1:27Speaker 4: year when the earnings and the outlook really disappointed for
- 1:30Speaker 4: twenty twenty six. So this latest read out, this latest
- 1:34Speaker 4: data really cements Eli Lilly as the leader in the
- 1:37Speaker 4: obesity space and it makes it much harder nowf and
- 1:39Speaker 4: Nova to come back from that and to try and
- 1:42Speaker 4: convince investors that things can actually get better.
- 1:46Speaker 1: Okay, so that's Novo Nordisk.
- 1:48Speaker 2: Let's turn next to Phrizenious Medical Care and their shares
- 1:52Speaker 2: also on the slide today.
- 1:54Speaker 1: Yeah, and that's because.
- 1:54Speaker 4: The outlook was seen as very disappointing for that company
- 1:57Speaker 4: that provides dialysis. So it's targeted broadly flat earnings in
- 2:01Speaker 4: twenty twenty six, and that is after a really big
- 2:04Speaker 4: surge in profit that we saw last year, and so
- 2:07Speaker 4: this moderation was not received very well by the market,
- 2:11Speaker 4: and the shes did for quite a bit this morning.
- 2:13Speaker 4: So the company has been undergoing this big turnaround that
- 2:16Speaker 4: included divestments, included a cost cutting program, but the results
- 2:20Speaker 4: for the fourth quarter to show that the profit gains
- 2:23Speaker 4: were really being driven by pricing and by that efficiency
- 2:27Speaker 4: rather than any patient growth.
- 2:29Speaker 1: So it doesn't look very sustainable in that way.
- 2:31Speaker 4: And so the outlook the numbers seem to signal that
- 2:34Speaker 4: this really big turnaround that that has been working on
- 2:38Speaker 4: is giving way, maybe quite quickly, to much more modest growth,
- 2:41Speaker 4: and so we're seeing that being quite disappointing for investors
- 2:44Speaker 4: this morning.
- 2:46Speaker 3: And lastly, the Spanish speaking world helping Telefonica to offset
- 2:51Speaker 3: European business worries.
- 2:54Speaker 4: Yeah, let's end on something a little bit more positive.
- 2:56Speaker 4: So Telefonica is in the green this morning.
- 2:59Speaker 1: That is because, yeah, it is in pretty good shape.
- 3:01Speaker 4: So growth in Spain and in growth in Brazil helped
- 3:04Speaker 4: offset some of that weakness in other European markets. So
- 3:07Speaker 4: things it seems that things have gotten a bit better
- 3:09Speaker 4: since the investor day back in November where the chairman
- 3:13Speaker 4: slashed the guidance for cash flows and also the dividend,
- 3:17Speaker 4: and since then there have been a lot of efficiency measures,
- 3:20Speaker 4: restructuring efforts, including job cuts and it seems that some
- 3:24Speaker 4: of those are starting to pay off.
- 3:26Speaker 1: So in Spain in particular, growth was really good.
- 3:29Speaker 4: It's one of Europe's most competitive telecom markets, but all
- 3:32Speaker 4: of the financial indicators grew last year for the first
- 3:36Speaker 4: time since two thousand and eight, so it's definitely much
- 3:39Speaker 4: better there. For other markets, there is some persistent weakness
- 3:43Speaker 4: in particularly in places like Germany where there's just a
- 3:46Speaker 4: lot of competition. There's competition with Deutsche Telecom, with Vodafone,
- 3:50Speaker 4: with one in one, so it's really limiting Telephonica's ability
- 3:54Speaker 4: to push through higher prices in that market in particular,
- 3:57Speaker 4: so it's definitely a weaker spot. The good earnings elsewhere,
- 4:01Speaker 4: good cash flow, and that was enough to make those
- 4:03Speaker 4: investors happy.
- 4:04Speaker 2: This morning the Stockmovers Report from Bloomberg Radio. Check back
- 4:09Speaker 2: with us throughout the day for the latest roundup of
- 4:11Speaker 2: companies making news on Wall Street and for the latest
- 4:14Speaker 2: market moving headlines. Listen to Bloomberg Radio Live, catch us
- 4:19Speaker 2: on YouTube, Bloomberg dot com, and on Applecarplay and Android
- 4:22Speaker 2: Auto with the Bloomberg Business app.